Effectiveness of Ecological Momentary Assessment Based Smoking Cessation Intervention

May 10, 2023 updated by: The University of Hong Kong

Low-intensity Ecological Momentary Assessment (EMA) for Smoking Cessation Intervention and Tobacco Control Policy Evaluation: a Randomized Controlled Trial Nested Within an EMA-based Observational Study

The EMA-based intervention in this proposal is aimed to motivate the majority of smokers who do not prefer to use traditional cessation aids for quitting and help them quit smoking. The smartphone application (app) and the EMA-based phone reminders at low cost and short intervention time make this approach attractive for the majority of smokers. Identification of accurate and specific pro-smoking cues in the real-word and real-time environmental cues via the app will provide valuable information to guide new tobacco control policies.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Study design:

The proposed study comprises a 2-arm (allocation ratio 1:1) pragmatic RCT to assess the efficacy of the EMA-based smoking cessation intervention and the EMA-based observational study. Throughout the 7-day participation, all recruited participants will complete an EoD survey and 4 time-based system-triggered EMA each day. The surveys will be prompted by a smartphone application (app) installed in their own mobile phones. The prompting time will be personalized and pre-scheduled by the participants. The information collected in the app will be used to develop an EMA-based intervention including a quit plan and 10-week quitting reminders and for an EMA-based observational study. I will randomly allocate half of the participants (intervention group) to receive the EMA-based intervention. All participants will then be contacted for a follow-up at 3- and 6-month.

Subjects:

This proposed study aims to recruit daily tobacco users, regardless of intention to quit.The inclusion criteria are: (1) daily consumption of tobacco products (including traditional cigarettes, electronic cigarettes, and heated tobacco products) in the past week; (2) age ≥18 years; (3) owning a mobile smartphone with internet access; (4) staying in Hong Kong during the 1-week EMA study period; and (5) able to read and write Chinese. Participants' smoking status will be confirmed by measuring exhaled carbon monoxide to be 4ppm or above, or saliva cotinine to be 30ng/ml or above. Because the proposed study aims to promote smoking cessation in smokers who do not plan to use smoking cessation aids, we will exclude smokers who (1) plan to use smoking cessation services or medication in the coming month or (2) using smoking cessation services, or using nicotine replacement therapy in the past 7 days. Smokers who reported having mental illnesses and female smokers who are pregnant are also excluded as they need more specific smoking cessation intervention.

Recruitment procedures:

Recruitment will be conducted both offline and online. In the outdoor recruitment, the recruitment staff first approach and distribute souvenirs (e.g., a tissue pack) to the smokers at outdoor smoking hotspots. If the smoker is willing to accept souvenirs and talk to the recruitment staff, the staff will ask further questions related to eligibility. Eligible participants will: (1) be given more detail about this project, (2) be invited to provide written consent, (3) be assisted in installing EMA app on their mobile phone and setting EMA schedule, (4) complete baseline questionnaire by paper form or Qualtrics. Due to the time-limited at outdoor recruitment, participants can complete baseline questionnaire after the recruitment session.

Research assistants will also send mass emails or advertisements through social media (e.g., Facebook, Instagram). Potential participants who are interested in this project can scan the QR code on the advertisement and complete the online application form (using Qualtrics). Our recruitment staff makes appointments with the potential participants to complete the recruitment procedures.

Ecological momentary assessment:

An EMA app will be developed to document all smoking cues and smoking-related behaviors. After installing the EMA app on participants' smartphones, participants need to input the five last digit numbers of their telephone number as an identifier and select the date they would like to start the EMA survey. Participants need to complete 5 time-based EMA surveys per day for 7 consecutive days, each EMA survey with an interval of three hours.

The EMA questions on smoking cues cover 4 domains: emotional, social, pattern, and withdrawal cues. Smoking-related behaviors include (1) smoking tobacco (traditional cigarettes, heated tobacco products, and electronic cigarettes) during the past 3 hours, (2) nicotine craving during the past 3 hours and type of craving (physical, psychological or social craving), (3) purchasing tobacco products during the past 3 hours. Whether the smoking-related behaviors have been due to the exposure to the pro-smoking cues will also be asked. Sleep quality will be asked by (1) did you experience insomnia problem (difficulty falling asleep, difficulty staying asleep, problems waking up too early) for last night (none, mild, moderate, severe, very severe), (2) how satisfied are you with your last night sleep pattern (score range from 0 very satisfied to 4 very dissatisfied) in first EMA for each day. 'Time to consume the first cigarette after waking' will be asked at the second EMA. Tobacco control policy, including health warnings on their tobacco pack; POS tobacco displays; smoking hotspots, and daily tobacco consumption, will be asked at the last EMA for each day.

Intervention:

Based on the EMA of each participant, a trained research nurse will review their (1) nicotine dependence; (2) intensity and frequency of reported cravings; and (3) the impact of exposure to pro-smoking cues on smoking behaviors. A personalized quit plan will be developed based on tailored suggestions from the US clinical practice guideline for smoking cessation, Smoking Cessation Information Kit (published by Department of Health), the theory of Health Action Process Approach, and the self-determination theory. Our recent studies showed that interventions based on these theories are effective. Half of the randomly selected participants (intervention group) will receive this quit plan via a nurse-led phone call, email, and WhatsApp. The nurse will then design a quit plan including (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant. Participants will then receive tailored quitting reminders via WhatsApp and voluntarily discuss their quit plan with the nurse in the subsequent 10 weeks.

Randomization, blinding, and allocation concealment:

The research staff will randomly assign participants on an individual level to intervention and control group using a 1:1 allocation ratio by sequentially numbered, opaque sealed envelope method. The principle will generate a list of random numbers using the random function of Excel. Then prepare about 450 identical, opaque, sealed, A5-sized envelopes, with a unique 3-digit serial number on the cover of each envelope as an identifier, and put the allocation code into the envelopes. All recruitment staff and participants will be concealed to the group allocation at recruitment. After a participant consents to the trial, the research staff will retrieve his/her information and open 1 envelope to allocate the recruited participant according to the card inside.

Participants and research staff of intervention delivery will not be blinded to the intervention because the intervention is behaviors. However, assessors of the follow-up and the research investigators will not be involved in the recruitment and intervention delivery and will be blinded to the group allocation (i.e. single-blinded design).

Follow-up All participants will be followed up via telephone by an allocation-blinded interviewer at 3- and 6-month after consenting to participation. Only the participants who report abstinence in the past 7 days will be invited to measure their exhaled CO with a Smokerlyzer and/or saliva cotinine level with a Cotinniene Saliva Test Device at their residence, workplace, or nearby, according to their preference.

Sample size:

To date, there has been no randomized controlled trial (RCT) to provide an estimate of effect size for the EMA-based intervention. Our team's previous RCT of testing a personalized smoking cessation intervention showed that the intention-to-treat biochemically validated abstinence at 3-month was 8%, the same as at 6-month7. From a previous network meta-analysis, the odd ratio of biochemically validated abstinence at 6-month follow-up for tailoring text messaging compared to minimal smoking cessation services (i.e., non-smoking cessation support) was 1.614. To detect a significant difference of quit rate between two groups with a power of 80% (to reduce type II error) at 5% significant level (type I error), a total of 436 participants (allocation ratio 1:1; 218 vs 218) is needed16. Our current outreach health promotion (funded by Health Care Promotion Scheme, project no. 01170418) showed that each month we can recruit 30 to 60 smokers to participate in the smoking cessation RCT. Considering the limited study period covered in this funding application, this proposed study targets to recruit 440 smokers in 11 months.

Data analysis:

The primary analysis will examine the effect of EMA-based intervention on biochemically validated abstinence at 3-month and the difference in the IBC-S score between the two groups. Intention-to-treat approach will be used to include all consented participants in the analysis and assume non-respondents at the 3-month follow-up as smokers and no change on the IBC-S score. A generalized estimating equation (GEE) analysis with exchangeable structure for the correlation matrix will be used for biochemically validated abstinence after adjusting unbalance baseline demographics and other variables that have been reported to be associated with smoking cessation. We will use linear regression adjusted for imbalance socio-demographics assessed at baseline to compare the score of IBC-S between intervention and control groups. Multiple imputation will be used to deal with missing values for baseline socio-demographics. All secondary and ancillary outcomes will be analyzed with either GEE (binary outcomes) or linear mixed models (continuous outcomes). Subgroup analysis of comparing the primary and secondary outcomes between intervention group participants who received both nurse-led phone calls plus instant messaging and instant messaging only will be conducted.

Study Type

Interventional

Enrollment (Actual)

459

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Hong Kong University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Daily consumption of tobacco products (including traditional cigarettes, electronic cigarettes, and heated tobacco products) in the past week;
  2. Age ≥18 years;
  3. Owning a mobile smartphone with internet access;
  4. Staying in Hong Kong during the 1-week EMA study period;
  5. Able to read and write Chinese
  6. Exhaled carbon monoxide will be measured and required to be 4ppm or above, or saliva cotinine to be 30ng/ml or above

Exclusion Criteria:

  1. Plan to use smoking cessation services or medication in the coming month
  2. Using smoking cessation services, or using nicotine replacement therapy in the past 7 days
  3. Having mental illnesses
  4. Female smokers who are pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
The intervention group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. The intervention group will receive 15-30 minutes of a nurse-led phone call, and 10-week instant messaging after completing the one-week EMA documentation.
Behavioral: EMA-based intervention
A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
Behavioral: EMA-based intervention
Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
No Intervention: Control
The control group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. No intervention will be provided to the control group after completing the one-week EMA documentation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incremental Behavior Change Towards Smoking Cessation (IBC-S) at 3-month follow-up
Time Frame: 3-month follow-up
Behavioral progression towards smoking cessation will be detected by 15-item Incremental Behavior Change towards Smoking Cessation. 15-item Incremental Behavior Change towards Smoking Cessation contains two parts: behavioral and cognitive changes. Item 1 to Item 12 are binary questions on a scale of 0 to 1 (0, no; 1, yes) to evaluate the behavioral changes. Cognitive changes are measured by item 13 to 15 on a scale of 0 to 4 (0, not at all; 4 always). Higher score means a better outcome.
3-month follow-up
Prevalence of biochemical validated abstinence at 3-month follow-up
Time Frame: 3-month follow-up

Tobacco abstinence in the past 7 days, which is validated using an exhaled carbon monoxide level of< 4 ppm, and a saliva cotinine level of < 30 ng/ml.

Noted:

  1. Suppose participants refuse to have a face-to-face exhaled carbon monoxide test due to the pandemic of COVID-19 in Hong Kong. In that case, the outcome will be validated by a cotinine saliva test device only.
  2. If participants use NRT, the outcome will be validated by exhaled carbon monoxide only.
3-month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of biochemical validated abstinence at 6-month follow-up
Time Frame: 6-month follow-up

Tobacco abstinence in the past 7 days, which is validated using an exhaled carbon monoxide level of< 4 ppm, and a saliva cotinine level of < 30 ng/ml.

Noted:

  1. Suppose participants refuse to have a face-to-face exhaled carbon monoxide test due to the pandemic of COVID-19 in Hong Kong. In that case, the outcome will be validated by a cotinine saliva test device only.
  2. If participants use NRT, the outcome will be validated by exhaled carbon monoxide only.
6-month follow-up
Prevalence of self-reported 7-day abstinence at 3-month follow-up
Time Frame: 3-month follow-up
Self-reported 7-day abstinence at 3-month follow-up
3-month follow-up
Prevalence of self-reported 7-day abstinence at 6-month follow-up
Time Frame: 6-month follow-up
Self-reported 7-day abstinence at 6-month follow-up
6-month follow-up
Self-reported use of smoking cessation service or medication from baseline at 3-month follow-up
Time Frame: 3-month follow-up
Use of smoking cessation service or medication from baseline at 3-month follow-up
3-month follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-report quit attempts at 3-month follow-up
Time Frame: 3-month follow-up
Number of quit attempts from baseline at 3-month follow-up
3-month follow-up
Self-efficacy to quit smoking at 3-month follow-up
Time Frame: 3-month follow-up
Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), the difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident). For the scale of measuring quitting importance and confidence, higher scores mean a better outcome and for the scale of measuring difficulty, higher scores mean a worse outcome.
3-month follow-up
Self-report satisfaction toward instant messages at 3-month follow-up
Time Frame: 3-month follow-up
Defined by rating the satisfaction of instant messages on a scale of 0 to 4 (0, very dissatisfied; 4 very satisfied)
3-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The University of Hong Kong

Collaborators

Health and Medical Research Fund

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 21, 2022

Primary Completion (Actual)

April 3, 2023

Study Completion (Anticipated)

June 1, 2023

Study Registration Dates

First Submitted

January 14, 2022

First Submitted That Met QC Criteria

January 14, 2022

First Posted (Actual)

January 28, 2022

Study Record Updates

Last Update Posted (Actual)

May 12, 2023

Last Update Submitted That Met QC Criteria

May 10, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 05190077

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Research data and documentation will be available upon request

IPD Sharing Time Frame

3 years after the completion of the relevant publications.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking Cessation

Clinical Trials on EMA-based intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe